Traditional deal diligence often overlooks the most critical question in pharmaceutical value creation: will payers actually reimburse at the price you expect? After seeing billions lost to optimistic pricing and reimbursement assumptions, a group of former HTA assessors, payers, and buy-side experts founded MARA Rating Company. Our purpose is clear—apply the rigor of credit ratings to market-access risk so you have the full picture before capital is committed.
To transform life-science investments by delivering transparent, data-driven ratings that quantify pricing and reimbursement risk—instilling confidence in every decision.
• MARA Rating (Complimentary) – A concise snapshot that delivers the asset’s MARA Rating alongside therapeutic-area and industry benchmarks, giving you an immediate read on pricing and reimbursement risk.
• Deep-Dive Report – An evidence-rich report that compares the asset head-to-head with market competitors. Radar visuals, and our ten-factor HTA framework dashboard highlight product strengths and flag potential pricing hurdles early.
• Tailor-Made Studies – Custom analyses built to your exact needs. We compare specific products, therapy areas, and historical outcomes to reveal the likelihood of a smooth pricing and reimbursement pathway for any asset, new or in-market. Each study is reviewed by our expert committee, arming acquirers, licensees, and investors with the insight to negotiate smarter—or walk away.
See pricing and reimbursement risk clearly.
Choose MARA Rating Company.
